Breakthrough Prostate Cancer Treatment Shows 40% Reduction in Risk of Death
A novel combination therapy is poised to significantly improve outcomes for men battling prostate cancer, offering a potential reduction in mortality risk of over 40%. The findings, stemming from a large-scale international trial, suggest a faster path to treatment availability than is typical for new medical advancements.
Prostate cancer remains the most common cancer diagnosed in men. According to data from the Institut National du Cancer, approximately 60,000 men in France are affected each year, resulting in around 8,000 deaths. These figures may soon decline, however, thanks to research conducted in Los Angeles.
A Global Trial Yields Promising Results
The innovative treatment involves combining two existing drugs – enzalutamide and leuprolide – already used in prostate cancer care. Researchers evaluated the efficacy of this combination in a clinical trial involving 1,000 patients across 17 countries. Participants were strategically divided into three groups: one receiving enzalutamide alone, another receiving leuprolide alone, and a third receiving the combined therapy.
The results, published on October 19, 2025, in The New England Journal of Medicine, revealed a striking disparity in outcomes. Neither enzalutamide nor leuprolide demonstrated a significant impact on survival rates when administered individually. However, the group receiving the combined treatment experienced a substantial 40.3% reduction in the risk of death after an average follow-up period of eight years.
Addressing a Critical Unmet Need
This discovery is particularly significant given the high rate of recurrence among prostate cancer patients. Approximately 40% of men who initially respond to treatments like radiotherapy or surgery experience a relapse. “After an initial successful treatment, some patients see their prostate cancer return aggressively and are at risk of their disease spreading rapidly,” explained Stephen Freedland, a urologist and co-senior author of the study.
The combination therapy offers a potential solution for these patients, providing a new avenue for combating aggressive, recurring disease.
Rapid Path to Patient Access
Unlike many medical breakthroughs that require extensive regulatory hurdles, this treatment may reach patients relatively quickly. Both enzalutamide and leuprolide have already been approved by the Food and Drug Administration (FDA), the agency responsible for drug authorization in the United States. This pre-approval status could expedite the authorization process for the combined treatment, offering hope for a swift improvement in patient care.
